

5 January, 2015

Appendix 3B - Revision

Due to an administrative error in the collation of acceptances from the recently completed pro-rata non-renounceable entitlement offer (Entitlement Offer), Altech Chemicals Limited (Altech/the Company) (ASX: ATC) provides a revised Appendix 3B and summary of offer acceptances (below).

Details of applications received (revised)

The Company received valid applications under the Entitlement Offer for 3,467,735 new shares, inclusive of applications for additional shares made by eligible shareholders in excess of their individual entitlement.

The Company received applications for 560,000 shares under the Shortfall Offer, which included an application for 250,000 shares from a related party to the Company's managing director Mr Iggy Tan, the issue of these shares is subject to shareholder approval which shall be sought at a general meeting of the Company to be convened in Q1 2015.

In total \$402,774 was raised from the Entitlement Offer.

Capital Structure

The capital structure of the Company is detailed in the attached appendix 3B, and is summarised below:

Fully paid ordinary shares quoted on the ASX	111,536,237
ASX quoted options (ex. \$0.20 on or before 31-05-15)	21,465,000
ASX quoted options (ex. \$0.10 on or before 15-12-15)	3,777,735
Unquoted options (various exercise prices and expiry dates)	12,633,333
Unquoted performance rights	15,384,580

ENDS

For more information, please contact:

Corporate

Iggy Tan
Managing Director
Altech Chemicals Limited
Tel: +61 8 9389 5557
Email: info@altechchemicals.com

Media Contact

Tony Dawe
Consultant
Professional Public Relations
Tel (office): +61 8 9388 0944
Email: tony.dawe@ppr.com.au

About Altech Chemicals (ASX: ATC)

Altech Chemicals Limited (Altech/the Company) is aiming to become one of the world's leading suppliers of **99.99% (4N) high purity alumina (HPA)** (Al_2O_3). HPA is a high-value product because it is the major source material for scratch-resistant artificial sapphire glass. Sapphire glass is used to produce a range of high-performance electronic applications such as LEDs, semi-conductors, phosphor display screens, as well as new emerging products such as smartphones and tablet devices. The global HPA market is approximately 19,040tpa (2014) and is expected to at least double over the coming decade.



Current HPA producers use an expensive and highly processed feedstock material such as aluminium metal to produce HPA. Altech produces 4N HPA directly from an ore feedstock, aluminous clay, from its Meckering deposit in Western Australia. The Company is now advancing a Bankable Feasibility Study (BFS) to develop a full-scale **4,000tpa HPA production** facility. The Altech process employs conventional and proven 'off-the-shelf' plant and technology to extract HPA from its **low-cost** and **low-impurity** aluminous clay feedstock, which results in **lower operating costs**.

Altech is a chemical processing group focused on creating a high-margin product to meet the growing global demand for the next generation of high-performance technologies.

Forward-looking Statements

This announcement contains forward-looking statements which are identified by words such as 'anticipates', 'forecasts', 'may', 'will', 'could', 'believes', 'estimates', 'targets', 'expects', 'plan' or 'intends' and other similar words that involve risks and uncertainties. Indications of, and guidelines or outlook on, future earnings, distributions or financial position or performance and targets, estimates and assumptions in respect of production, prices, operating costs, results, capital expenditures, reserves and resources are also forward looking statements. These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions and estimates regarding future events and actions that, while considered reasonable as at the date of this announcement and are expected to take place, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of our Company, the Directors and management. We cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and readers are cautioned not to place undue reliance on these forward-looking statements. These forward looking statements are subject to various risk factors that could cause actual events or results to differ materially from the events or results estimated, expressed or anticipated in these statements.

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Altech Chemicals Limited

ABN

45 125 301 206

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|--|--|
| 1 | +Class of +securities issued or to be issued | (a) Ordinary shares
(b) Options |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | (a) 3,777,735 ordinary shares
(b) 3,777,735 options |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | (a) Ordinary shares rank pari passu with existing ordinary shares
(b) Options are exercisable at \$0.10 each, are quoted and expire 5pm 15 December 2015. Ordinary shares issued from the exercise of options will rank pari passu with existing ordinary shares. |

+ See chapter 19 for defined terms.

<p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>(a) Ordinary shares rank pari passu with existing ordinary shares.</p> <p>(b) Options are quoted and upon exercise the issued ordinary shares will rank pari passu with existing ordinary shares.</p>
<p>5 Issue price or consideration</p>	<p>(a) Ordinary shares: \$0.10 per share</p> <p>(b) Options were issued for nil consideration</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>To provide funds to enable the Company to complete a Bankable Feasibility Study into the development of a High Purity Alumina (HPA) processing plant and for corporate and general working capital purposes.</p>
<p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>Yes</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>5 November 2014</p>
<p>6c Number of +securities issued without security holder approval under rule 7.1</p>	<p>(a) Ordinary shares: Nil</p> <p>(b) Options: Nil</p>
<p>6d Number of +securities issued with security holder approval under rule 7.1A</p>	<p>Nil</p>
<p>6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)</p>	<p>n/a</p>

6f	Number of securities issued under an exception in rule 7.2	(a) Ordinary Shares: 3,777,735 (b) Options: 3,777,735								
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	n/a								
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	n/a								
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 16,163,775 7.1A: 10,775,850								
7	Dates of entering +securities into uncertificated holdings or despatch of certificates	29 December 2014								
8	Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	<table><tr><th>Number</th><th>+Class</th></tr><tr><td>111,536,237</td><td>Ordinary Shares</td></tr><tr><td>21,465,000</td><td>Options (exercise price \$0.20, expiring 31 May 2015)</td></tr><tr><td>3,777,735</td><td>Options (exercise price \$0.10, expiring 15 December 2015)</td></tr></table>	Number	+Class	111,536,237	Ordinary Shares	21,465,000	Options (exercise price \$0.20, expiring 31 May 2015)	3,777,735	Options (exercise price \$0.10, expiring 15 December 2015)
Number	+Class									
111,536,237	Ordinary Shares									
21,465,000	Options (exercise price \$0.20, expiring 31 May 2015)									
3,777,735	Options (exercise price \$0.10, expiring 15 December 2015)									

⁺ See chapter 19 for defined terms.

- 9 Number and ⁺class of all ⁺securities not quoted on ASX (including the securities in section 2 if applicable)

Number	⁺ Class
8,000,000	Ex. \$0.20, Expiry 31-05-2015
1,000,000	Ex. \$0.20, Expiry 18-12-2017
1,000,000	Ex. \$0.25, Expiry 18-12-2017
1,000,000	Ex. \$0.30, Expiry 18-12-2017
500,000	Ex. \$0.20, Expiry 08-02-2015
333,333	Ex. \$0.30, Expiry 04-02-2015
200,000	Ex. \$0.25, Expiry 15-03-2015
600,000	Ex. \$0.20, Expiry 31-01-2017
384,580	Performance Rights (Employees)
15,000,000	Performance Rights (Managing Director)

- 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Part 2 - Bonus issue or pro rata issue

- 11 Is security holder approval required?

- 12 Is the issue renounceable or non-renounceable?

- 13 Ratio in which the ⁺securities will be offered

- 14 ⁺Class of ⁺securities to which the offer relates

- 15 ⁺Record date to determine entitlements

- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

- 17 Policy for deciding entitlements in relation to fractions

- 18 Names of countries in which the entity has ⁺security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

- | | | |
|----|---|--|
| 19 | Closing date for receipt of acceptances or renunciations | |
| 20 | Names of any underwriters | |
| 21 | Amount of any underwriting fee or commission | |
| 22 | Names of any brokers to the issue | |
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders | |
| 25 | If the issue is contingent on +security holders' approval, the date of the meeting | |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 28 | Date rights trading will begin (if applicable) | |
| 29 | Date rights trading will end (if applicable) | |
| 30 | How do +security holders sell their entitlements <i>in full</i> through a broker? | |
| 31 | How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | |

+ See chapter 19 for defined terms.

32 How do ⁺security holders dispose of their entitlements (except by sale through a broker)?

33 ⁺Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) ☒ Securities described in Part 1

(b) ☐ All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 ☒ If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders

36 ☒ If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37 ☐ A copy of any trust deed for the additional ⁺securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which +quotation is sought					
39	Class of +securities for which quotation is sought					
40	<p>Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 					
41	<p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another security, clearly identify that other security)</p>					
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%; padding: 5px;">Number</th> <th style="width: 50%; padding: 5px;">+Class</th> </tr> </thead> <tbody> <tr> <td style="height: 100px;"></td> <td></td> </tr> </tbody> </table>	Number	+Class		
Number	+Class					

+ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



Date: 5 January 2015 (Director/Company Secretary)

Print name: Shane Volk

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	107,725,202
Add the following: <ul style="list-style-type: none"> Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	33,300 Nil Nil
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil
“A”	107,758,502

+ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 <i>[Note: this value cannot be changed]</i>
Multiply "A" by 0.15	16,163,775
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items 	
"C"	Nil
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15 <i>Note: number must be same as shown in Step 2</i>	16,163,775
Subtract "C" <i>Note: number must be same as shown in Step 3</i>	-
Total ["A" x 0.15] – "C"	16,163,775 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	107,758,502
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	10,775,850
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: <ul style="list-style-type: none"> • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items 	Nil
“E”	Nil

+ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 <i>Note: number must be same as shown in Step 2</i>	10,775,850
Subtract "E" <i>Note: number must be same as shown in Step 3</i>	-
Total ["A" x 0.10] – "E"	10,775,850 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.

ALTECH CHEMICALS LIMITED
ALTECH CHEMICALS LIMITED OPTIONS EXP 15/12/15 @ \$0.10

Page - 1

Holder name	Designation
1 LAKE MCLEOD GYPSUM PL	
2 * AUST MINERAL INV GRP PL	
3 * WAYLEN BAY CAP PL	
4 CALCAT RES PL	
5 S/F A/C	C FORRESTER S/F A/
6 * THOMAS DAVID R + J G	S/F A/C
7 TSE MGMT PL	TSE EXECUTIVE S/F
8 * BLACK MICHAEL F + L R	PERTH SURGICAL SUP
9 TAYLOR RIE	
10 TAYLOR DAVID	
11 * QUINLAN DANIEL JOHN	KEIZER A/C
12 KEIZER DIRK + LENA	
13 BIRD BARRY WILLIAM	
14 VOLK S R + SITUMORANG S V	VOLKSVS S/F A/C
15 BARNETT CRAIG	BARNETT & BIENIASZ
16 GIBBS MALCOLM ERIC	
17 KHEW HAN PIN + AH YOOK	KHEW S/F A/C
18 SABEGEHA PL	CASENCO S/F A/C
19 GALLOWAY REX ANTHONY + K	PENGUIN INV S/F A/
20 TIGHE JOHN DESMOND	
OSCAR JAMES PL	AJCR S/F A/C

*** Top 20 total ***

** All holders included

* - Denotes merged holder

Spread & Top 20 Listing

- Current Status -	Units	% of issued
983,750	26.04%	
500,000	13.24%	
359,488	9.52%	
200,000	5.29%	
149,750	3.96%	
131,275	3.46%	
128,120	3.33%	
100,000	2.65%	
75,000	1.99%	
75,000	1.99%	
70,000	1.85%	
62,500	1.65%	
43,100	1.14%	
40,000	1.06%	
40,000	1.06%	
28,000	.74%	
27,500	.73%	
25,000	.66%	

3,213,483

85.07%

Date - 2/01/2015 Time - 16.58.04

User - KIERAN

- As at:24/12/14 -

Units % of issued

983,750	23.78%	1
500,000	12.09%	3
718,976	17.38%	2
200,000	4.83%	4
149,750	3.62%	5
131,275	3.17%	6
128,120	3.10%	7
100,000	2.42%	8
100,000	2.42%	9
75,000	1.81%	10
75,000	1.81%	11
75,000	1.81%	12
70,000	1.69%	13
62,500	1.51%	14
43,100	1.04%	15
40,000	.97%	16
40,000	.97%	17
28,000	.68%	18
27,500	.66%	19
25,000	.60%	20

3,572,971

86.36%

ALTECH CHEMICALS LIMITED
 ALTECH CHEMICALS LIMITED OPTIONS EXP 15/12/15 @ \$0.10
 Page - 2

Date - 2/01/2015 time - 16:58.04
 User - KIERAN

Spread Analysis Listing

<u>Spread of Holdings</u>	<u>Holders</u>	<u>Securities</u>	<u>% of issued capital</u>
NIL holding			
1 - 1,000	4	3,406	.09 %
1,001 - 5,000	27	74,298	1.97 %
5,001 - 10,000	16	134,973	3.57 %
10,001 - 100,000	34	1,112,675	29.45 %
100,001 -	7	2,452,383	64.92 %
Total on register	88	3,777,735	100.00 %
Total overseas holders	2	200,000	5.29 %
<u>Analysis by location</u>			
Overseas	2	200,000	5.29 %
Australia :	84	3,560,835	94.26 %
ACT	0		.00 %
NSW	11	93,604	2.48 %
VIC	20	403,860	10.69 %
QLD	8	58,163	1.54 %
SA	4	63,100	1.67 %
WA	38	2,904,608	76.89 %
TAS	3	37,500	.99 %
NT	0		.00 %
Address unknown	2	16,900	.45 %
Total overseas holders	88	3,777,735	100.00 %

** ALL holders included

*** Common holders merged into one holding